UK markets closed

Novartis AG (NVS)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
98.35+1.07 (+1.10%)
At close: 04:00PM EDT
98.10 -0.25 (-0.25%)
After hours: 05:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close97.28
Open98.50
Bid97.00 x 1000
Ask100.00 x 1100
Day's range97.43 - 98.55
52-week range92.19 - 108.78
Volume2,233,187
Avg. volume1,578,035
Market cap201.138B
Beta (5Y monthly)0.47
PE ratio (TTM)23.99
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.78 (3.88%)
Ex-dividend date07 Mar 2024
1y target estN/A
  • Insider Monkey

    Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript

    Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript April 23, 2024 Novartis AG isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and good afternoon, and welcome to the Novartis Q1 2024 Results Release Conference Call and Live Webcast. […]

  • Zacks

    Company News for Apr 24, 2024

    Companies in The News Are: UPS,PM,NVS,IVZ

  • Benzinga

    FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors

    Tuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs. Related: Novartis Stock Gains On European Drugm